Theriva Biologics wins Spanish regulator clearance for VIRAGE2 VCN-01 pancreatic cancer trial

Theriva Biologics has received authorization from Spain’s AEMPS to initiate the VIRAGE2 Phase 2a trial of VCN-01 for metastatic pancreatic cancer. The study aims to evaluate more frequent dosing in combination with gemcitabine/nab-paclitaxel, with results intended to inform a potential Phase 3 program.

Theriva Biologics received authorization from Spain’s AEMPS to start the VIRAGE2 Phase 2a trial of VCN-01 in metastatic pancreatic cancer. * The study will test more frequent dosing in combination with gemcitabine/nab-paclitaxel, aiming to inform a potential Phase 3 program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theriva Biologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070800OMX_____CNEWS_EN_GNW9757603_en) on July 07, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)